Editorial: Advances in the pharmacotherapy of chronic pelvic pain conditions

This editorial reviews advances in pharmacotherapy for chronic pelvic pain, outlining evidence from five original preclinical/clinical studies and one Phase II clinical trial, with high-level discussion of multimodal, individualized approaches and viscera-brain axis mechanisms. It summarizes key findings including: AO+BS reducing mechanical pain persistence and spinal microgliosis in a mouse vulvodynia-like CFA model; GABA-Mo reducing inflammatory and some pain outcomes in DNBS-induced irritable bowel syndrome in rats (with a need for further mechanistic confirmation); gabapentin response predictors in women with unexplained CPP; and complementary studies on endometriosis, prostatitis, and pelvic inflammatory disease that largely emphasize anti-inflammatory/nociceptive pathways and acknowledge limitations such as need for longer/dose optimization and further mechanistic work. A major caveat is that this paper is an editorial/Research Topic overview rather than a systematic evaluation of all evidence. Relevance to endometriosis: the editorial explicitly includes a study by Wang et al. showing evodiamine inhibits EBV-related endometriosis development via ERβ suppression, making endometriosis a substantive component of the Research Topic despite the paper’s broader chronic pelvic pain scope.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works